drugset
drugset / Trial / NCT05775666

UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

NCT05775666 ↗

Phase 1 Unknown 87 enrolled Peking University UTC Therapeutics Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of UCLM802 (Anti-Mesothelin CAR-T) cell injection in patients with Mesothelin-positive advanced malignant solid tumors.

Timeline

Start
2023-03
Primary completion
2024-05
Completion
2025-01

Drugs

EvaluationDrugModalityDoseRoute
Subject UCLM802 Unknown — —

Indications

cancer